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This is the third in a series of four articles
that highlight the changing nature of global
health institutions.
Introduction
Conducting basic research, translating it
into the development of new health tools,
and delivering products to patients in need
of them are core functions of an effective
global health system [1]. Yet performing
these functions is a particular challenge for
diseases that primarily affect the poor in
low-income countries, partly because ef-
forts to understand diseases and develop
tools to combat them are often detached
from efforts to deliver interventions. For
malaria, the global health system has
evolved over the past century to integrate
better the research, development, and
delivery (R&D&D) of new products to
treat and control the disease. This article
traces that evolution and extracts lessons
applicable to the many new challenges
currently facing the global health system.
Historically, global investment in ma-
laria research has been disproportionately
small relative to its disease burden.
Research funding in endemic countries
was seriously limited by resource and
capacity constraints, while funding agen-
cies in industrialized countries were pri-
marily concerned with domestic health
issues, with the important exception of
military needs to control malaria. Recent-
ly, however, global malaria R&D invest-
ments have increased dramatically, from
an estimated $84 million in 1993 [2] to
$323 million in 2004 [3], with a new focus
on malaria’s impacts on people in endemic
countries.
In malaria control, there has been a
concomitant shift from time-limited, cen-
tralized efforts—often relying on single
interventions—toward a more decentral-
ized, continuous effort using multiple
approaches. Malaria is no longer seen
primarily as a biomedical problem, but
rather as a complex ecological system in
which humans, mosquitoes, and parasites
are interconnected. Malaria has also in-
creasingly been characterized as a ‘‘global’’
and regional rather than a national or local
problem. This has led to changed concepts
of governance. Such governance has
changed in two ways: (1) from an essentially
‘‘top-down’’ process from international to
national or local players to an active
interplay between local and global players,
and (2) from a system that centered on the
World Health Organization (WHO), with
little attention to national governments in
endemic countries, to one in which state
and non-state actors cooperate across
multiple dimensions, emphasizing inclusion
and engagement of local communities.
Today, for the first time, the principal
constraints to malaria control may be more
political and managerial than financial or
technical.
This article explores the changing
global health system for malaria research
and the delivery of research products to
those at risk, including the organizations
and actors involved, and the arrangements
that govern their interactions (for more
about these actors and arrangements, see
the first article in this four-part series [1]).
Following Alilio and colleagues [4], we
have divided the evolution of malaria
R&D&D into three periods (Table 1);
although these divisions are somewhat
arbitrary, they highlight major shifts in
the system’s development. Finally we
address the lessons learned and speculate
about the future.
Phase I. Late Nineteenth
Century through the 1950s:
National Public Goods
R&D
The early driver of malaria research was
the desire of the European colonial powers
to protect their own nationals and the
economic interests in their colonies. This
investment led to many discoveries, in-
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and transmission cycle of malaria. Later,
when malaria debilitated allied soldiers in
World War II (WWII), military needs
drove malaria R&D. None of the principal
malaria medicines of the twentieth century
would have been discovered without
military R&D [5–8]. Even insecticide-
treated bed nets (ITNs) [9] and household
spraying with DDT were used effectively
by the allied militaries in WWII [6,10].
During this long period, innovation
followed a distinct trickle-down pattern.
Researchers in the North produced knowl-
edge to serve their own national needs,
and only later was it applied for the benefit
of low-income countries. While these
R&D efforts ultimately created global
benefits, the institutions that guided and
benefited from the research were in rich
countries. The drawback for low-income
countries was that tools developed for
militaries of the North were not necessarily
well-suited for civilians in the South. Cost
was not a major issue for the North, and
because antimalarial drugs were targeted
at adults, testing in children was a low
priority, although children account for
most malaria deaths. As the US Military
Infectious Diseases Research Program
recently pointed out, ‘‘Preventing death
in children and keeping soldiers healthy
and effective are distinct goals requiring
different research strategies’’ [11].
Delivery
The association between swamps, mos-
quitoes, and malaria has long been appre-
ciated [12]. By the time of the Roman
Empire, bed nets, decoy animals to attract
mosquitoes, swamp drainage, and housing
prohibitions in mosquito breeding areas
were used to control malaria. The cluster-
ing of ‘‘marsh fever’’ among those living
near smelly swamps led to the miasma
theory of disease, that foul ‘‘mala aria’’ (bad
air in Italian, from which the name malaria
derives) from decomposed matter (mias-
mas) was the cause. Efforts at control were
local and often misguided, yet sometimes
effective, for example drainage of swamps
and closing of mill ponds in the US in the
nineteenth century.
Evidence-based systematic attempts to
control malaria at a population scale date
from the beginning of the twentieth
century, and were based on the under-
standing of the transmission cycle and
recognizing quinine’s therapeutic value.
Control programs were used in large,
expensive works projects threatened by
malaria (and yellow fever) and targeted at
workers and managers from industrialized
countries, such as the Suez and Panama
Canal projects. Multiple strategies were
adopted, including manual clearance of
mosquito larvae, removal of breeding sites,
leveling and oiling of roads to eliminate
water pools, use of clothing to prevent
mosquito bites at dusk, burning of pyre-
thrum indoors, larviciding with chemicals,
treatment with quinine, use of window
screens, and collection of indoor resting
mosquitoes post-feeding. These strategies
were effective in the limited scope of the
effort. In the late 1930s, Fred Soper of the
Rockefeller Foundation and 40,000 work-
ers in Brazil successfully eradicated Anoph-
eles gambiae, which had recently been
imported, using pyrethrum spraying, lar-
viciding with Paris Green (copper acet-
oarsenite), and elimination of breeding
sites [13].
In 1946, the US Centers for Disease
Control (CDC) was established in Atlanta,
Georgia as the successor to the WWII
Malaria Control in War Areas Agency,
primarily to eradicate malaria in the
southern states. According to a history of
the CDC, ‘‘Pursuit of malaria was by far
the most absorbing interest of CDC during
its early years, with over 50 percent of its
personnel engaged in it’’ [14]. Malaria
transmission in the US was eliminated.
Phase II. 1960s–1980s: The
International Health
Perspective
Phase I had involved nationally focused
programs concerned with domestic social
well-being (malaria in the southern US),
economic gain (the canal projects), or
military needs (wars in malaria zones).
But subsequent years witnessed a phase of
internationalization in public health, with
rapid decolonization, the launch of na-
tional foreign aid initiatives amidst height-
ened Cold War tensions, and new faith in
the potential of science and technology.
R&D
In phase II, the relevant actors were
increasingly viewing the world as interde-
pendent [15], with greater emphasis on
international health needs. The Special
Programme for Research and Training in
Tropical Diseases (TDR) was established
within WHO in 1975, and played a key
role in building malaria research capacity
in developing countries, particularly in
Africa where few malaria researchers
existed at the time of political indepen-
dence for the former colonies. TDR also
established international networks of aca-
demic centers for tropical disease research,
a model that the public–private product
development partnerships would later
emulate [16]. These national–internation-
al partnerships proved to be essential for
the development of critical new tools,
including artemisinin combination therapy
and ITNs still in use today [9,17,18].
During this era the private foundations
reemerged as a force, for example the
Great Neglected Diseases (GND) of Man-
kind Biomedical Research Network
launched by Kenneth Warren of the
Rockefeller Foundation [19]. Catalyzed
by GND funds, a stream of young
scientists from developing and developed
nations were attracted to work with
Table 1. Evolution of institutional arrangements for malaria R&D.
Phase Purpose of R&D Institutions Targeted End-Users Funding Targeted Diseases
I: Late Nineteenth Century
through the 1950s
National public goods Industrialized countries Public, private Malaria, yellow fever
II: 1960s–80s International health programs (e.g., TDR,
Fogarty International Center, Rockefeller
Foundation)
Developing countries Public, philanthropic Malaria and other tropical
infectious diseases
III: 1990s–2000s Global health partnerships neglected
disease R&D (e.g., PDPs)
Developing countries Public, philanthropic,
private sector
Malaria, tuberculosis, HIV/
AIDS and neglected tropical
infectious diseases
IV: The Future Global public goods for global health Global Public, philanthropic,
private sector
All types
doi:10.1371/journal.pmed.1000179.t001
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network on problems such as malaria in
the laboratory and the field.
Compared to the previous period,
institutions for R&D were broader in
scope, more international, and targeted
low-income country needs. However, as
the Rockefeller Foundation’s Tim Evans
later noted, GND produced ‘‘improved
basic knowledge about poorly understood
tropical diseases….[but] no explicit strat-
egy to translate new knowledge into drug
or vaccine development’’ [20]. By the late
1980s the GND was winding down, TDR
was seriously underfunded for its broad
mandate, and the pharmaceutical industry
had largely withdrawn from tropical
infectious disease research. The existing
R&D system could not meet the vast
health needs of low-income countries. The
research enterprise had simultaneously
succeeded and failed.
Delivery
In 1955, based on the wartime success
of DDT, WHO initiated an ambitious
attempt to eradicate malaria by eliminat-
ing the vector. However, by 1969 the
Global Malaria Eradication Programme
(in fact it was never global, excluding
much of sub-Saharan Africa from the
outset) was considered to have failed.
The program had nevertheless achieved
considerable success in 25 countries in
Africa, Asia, Europe, North America, and
the Caribbean, primarily relatively rich
and island countries and a few poor
countries with good health infrastructure
and seasonal malaria [21]. There were
many reasons to give up the effort,
including donor funding fatigue, local
resistance to the imposition of control
measures, insecticide resistance, and the
difficulty of mosquito eradication in many
ecosystems. Efforts reverted to control
[22], and with the momentum for primary
health care and the 1978 Alma Ata
declaration calling for ‘‘Health for All’’
by the year 2000, malaria control was
incorporated into primary care programs.
With the loss of visibility, combined
with waning global interest and dwindling
funding for research and control, malaria
was soon overshadowed by the emerging
HIV/AIDS epidemic in the 1980s. Be-
tween 1975 and 1994, malaria control was
financed mostly as bilateral assistance to
endemic countries, with yearly contribu-
tions of less than $20 million, for an
estimated $364 million over 20 years. The
impact of the ‘‘Silent Spring’’ movement
and the near total cessation of DDT
production [23], accompanied by rapid
spread of resistance to the nearly ideal
antimalarial chloroquine, contributed to
the resurgence of malaria, including in
places where it had formerly been con-
trolled. Malaria research and control had
itself become a neglected initiative.
Phase III. 1990s to the Present:
Global Health and Malaria
Research and Control
Many factors have led to the consider-
ation of health as a global imperative over
the past two decades, particularly the
disparate burden of HIV in poor nations
and the AIDS activist movement, which
revived a human rights approach to health
care. With these changes in the value
system and increasing attention to the
concept of global public goods, malaria
R&D and delivery have become priorities
again.
R&D
In 1990, the independent Commission
on Health Research for Development
argued in its seminal report, Health Re-
search-Essential Link to Equity in Development,
that research had long been ‘‘under-
recognized and neglected’’ as a tool to
mitigate growing global inequities in
public health [24]. With increasing glob-
alization of trade, travel, information, and
disease, health in general and R&D in
particular were increasingly framed as
‘‘global’’ rather than ‘‘international,’’ con-
cerned with ‘‘the health needs of the
people of the whole planet above the
concerns of particular nations’’ [25]. This
change also underscored ‘‘the growing
importance of actors beyond governmen-
tal or intergovernmental organizations’’
[24]. The report of the WHO Ad Hoc
Committee on Health Research Relating
to Future Intervention Options set prior-
ities for global health research and recom-
mended an approach to allocate research
funding [26]. Because confidence in the
leadership at WHO among key global
players was at an all-time low, an inde-
pendent organization, the Global Forum
for Health Research, was established in
Geneva to catalyze and monitor invest-
ments in research relevant to the world’s
poorest people [27].
Malaria was a good example of a
neglected disease in 1990, as both public
and private actors had largely retreated
from malaria research, even though drug-
resistant malaria was spreading across the
globe. In 1996, Harold Varmus, then
Director of the US National Institutes of
Health (NIH), concluded that malaria
R&D merited increased funding because
of its global impact and the potential for
scientific progress with increased funding.
The same year, the UK-based Wellcome
Trust reported on the domination of
malaria research by scientists from the
North [2]. In part because WHO was not
deemed to have sufficient scientific depth
or resources to address these disparities,
the Multilateral Initiative on Malaria
(MIM) was established in 1998 as a joint
effort of northern country health research
and bilateral aid agencies [28]. MIM
rapidly improved channels for information
flow between researchers in the North and
South through data sharing and internet-
based library access; established a reposi-
tory for patient-, parasite-, and vector-
derived chemical entities and genomes for
research; provided research funds for
African scientists through TDR; and
initiated a regular Pan African Malaria
conference to bridge the malaria research
and control communities. The MIM
Secretariat, based successively at the Well-
come Trust, the Fogarty International
Center at NIH, and the Karolinska
Institute, moved to its first African home
in Tanzania in 2006, although securing
long-term financial support remains a
vexing problem. Enlightened leadership
and commitment from the elite science
funding agencies was the essential catalyst
behind these changes.
By the late 1990s, the increasing self-
confidence of senior African scientific
leaders and maturation of young African
malaria researchers into senior leaders,
and recognition of their contributions to
knowledge generation, placed them at the
center of research planning and progress
in malaria. Trainees in basic sciences,
entomology, epidemiology, biostatistics
and bioinformatics, sociology, behavioral
sciences, and public health now could play
key roles and become deeply involved in
institutional leadership and management.
The creation of MIM also pushed forward
the visibility of malaria as a global
problem, engaged leading research fund-
ing institutions in the North, and support-
ed a global research network to link
research to control. These actions laid
the immediate groundwork for the launch
of public-private–product development
partnerships (PDPs) for malaria.
With the support of major foundations,
PDPs emerged in the 1990s to address a
glaring failure of existing institutional
arrangements for R&D—that market-in-
centives had proven insufficient to drive
investment in new tools for neglected
diseases [29]. PDPs have redefined roles
and expectations, with the public sector
playing a stewardship and funding role,
the private sector contributing materials
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investing a significant share of the funds.
New PDPs doing malaria research have
been created, including Medicines for
Malaria Venture (MMV), Malaria Vac-
cine Initiative (MVI), Drugs for Neglected
Diseases Initiative (DNDi), and the Insti-
tute for OneWorld Health (iOWH). Thus
far, two new fixed-dose combination
malaria treatments based on artemisinin
derivatives (DNDi) [30], a lower-cost
synthetic method to produce artemisinin
(iOWH) [31], and a licensed pediatric
formulation of an artemisinin combination
drug and a pipeline of new compounds in
development to address emerging drug
resistance (MMV) [32] have resulted.
Though relatively new, PDPs have rein-
vigorated product development for malar-
ia and other neglected diseases [33].
Furthermore, by placing affordability and
accessibility at the center of their missions,
they promote the concept of health R&D
as a global public good [34]. Importantly,
PDPs are explicitly expected to develop
products well-adapted for use in low-
income countries [35]. Nevertheless, the
PDPs are relatively young, and it remains
to be seen if they can efficiently deliver on
their early promise over the long haul.
Local initiatives are now apparent as
well. The African Malaria Network Trust
[36] and the Malaria Clinical Trials
Alliance [37] are African-led initiatives to
strengthen malaria-related R&D capaci-
ties in Africa. They collaborate with
northern partners and malaria PDPs to
support African research institutions to
develop products up through Phase III
clinical trials. This reflects the recognition
of African malaria scientists with the skills
to conduct basic and clinical research and
compete for funding, and reinforces the
new norm that neglected disease research
should involve endemic-country scientists
and be targeted to meet low-income
country needs.
Delivery
In 1992, the WHO Ministerial Confer-
ence on Malaria in Amsterdam [38]
outlined a broad set of measures to reduce
the burden of malaria, including early
diagnosis and treatment, selective and
sustainable preventive measures, early
identification of epidemics and rapid
responses to contain them, and strength-
ening of local capacities in basic and
applied research. Much of this agenda
was supported by northern research agen-
cies, not WHO. To reestablish a central
role for WHO, the newly elected Director
General, Gro Bruntland, in 1998 estab-
lished the Roll Back Malaria (RBM)
Partnership as a ‘‘Cabinet Project’’ report-
ing directly to her [39]. It signaled a new
order of business at WHO—a global
program partnership—responding to the
widely held belief that malaria could not
be controlled by governments and WHO
alone but needed multiple public and
private partners to succeed. The World
Bank, UNICEF, DFID, USAID, founda-
tions, NGOs, and the private sector
quickly joined RBM, together with na-
tional governments and their malaria
control agencies.
RBM’s mandate was to seek greater
funding, raise awareness of malaria as a
global problem, harmonize activities of the
partners and support development of
effective national programs. However,
heavy-handed management by the Secre-
tariat at WHO led to dissatisfaction with
progress among the partners and with the
manner in which they were being en-
gaged. An external evaluation, required by
the partners, damned with faint praise the
accomplishments of the first four years,
noting that advocacy was not supported by
data, decision-making was inefficient, ac-
countability within the Partnership was
lacking, reductions in the malaria burden
had been ‘‘slower than anticipated,’’
countries ‘‘receive inadequate and some-
times inconsistent technical advice,’’ and
insufficient attention was given to ‘‘multi-
sectoral approaches, particularly as re-
gards private sector activity’’ [40]. Since
then, RBM’s performance has improved.
RBM’s recently issued Global Malaria
Action Plan outlining strategies, costs,
goals, and timelines is a major accom-
plishment, with multiple partner inputs.
RBM is commissioning an independent
evaluation to appraise the ‘‘governance;
management; ability to convene, coordi-
nate and harmonize RBM partners and
stakeholders; and its impact on malaria
efforts at country level’’ [41].
The Global Fund to Fight AIDS,
Tuberculosis and Malaria (GFATM) was
founded in 2002 as a new international
financing mechanism for these three
diseases and to harness the capacities of
public, private, and civil society actors at
both global and national levels [42].
GFATM was based on the premise that
success depended on the involvement of
multiple state and non-state actors. It was
explicitly created as a public–private entity
outside of and independent of the UN
system. Furthermore, the concentration of
funds from multiple public and private
sources in GFATM (which totaled $1.6
billion for malaria control between 2002
and 2007) was intended to decrease prior
fragmentation of funding schemes. Despite
increasing multilateralism from many
global health actors, the US has been a
reluctant partner in GFATM since
its founding, preferring to invest most of
its significantly increased commitment
through bilateral programs, such as the
President’s Emergency Fund for AIDS
Relief (PEPFAR) and the President’s
Malaria Initiative (PMI). Total US pledges
to GFATM from its inception through
January 2009 amount to $4 billion. The
Obama administration’s budget request
for 2010 includes a 36% increase in
malaria support, a 2.5% increase for
PEPFAR, but no change in funding for
GFATM, thus continuing the major
emphasis on bilateral program support.
Phase IV. The Future: Lessons
Learned and Global Public
Goods for Global Health
The past 30 years has witnessed signif-
icant shifts in the types of actors and the
roles they play in malaria research and
control, with gradually increasing integra-
tion of the R&D&D communities. With
these changes, a number of new modes of
operation have been established that seem
certain to continue, such as: (1) a more
central role for endemic-country research-
ers in an increasingly globalized research
system; (2) direct funding to local research-
ers and institutions; (3) the involvement of
affected communities not only as targets of
interventions but as co-producers of re-
sults; (4) new actors taking on tasks
formerly vested in WHO; and (5) new
PDPs to drive research to unmet needs
and new product development. These
developments bode well for achieving the
prospects for new, effective, adapted, and
affordable tools for malaria
A new challenge to the global health
system is the recent decision by the Bill
and Melinda Gates Foundation, in addi-
tion to its support of malaria PDPs, to
place malaria eradication back on center
stage [43]. Not all experts agree that
malaria eradication is feasible or desirable
[44]. Regardless of the validity of the
criticism, it is necessary to continue to
develop and apply new tools to eliminate
malaria as a significant public health
problem, as disease reduction is the
necessary antecedent to any attempt at
eradication of the parasite.
New mechanisms for partnerships
among global and national organizations
have pioneered new approaches to financ-
ing and governance of programs, such as
GFATM and RBM, along with major
bilateral investments, such as PEPFAR
and PMI. In addition, the interests of the
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development to tackle growing drug and
insecticide resistance. These innovations
have focused on neglected infectious dis-
eases that by definition affect only develop-
ing countries. Such innovations leave the
question unanswered of who contributes to
and who benefits from R&D for diseases
that affect all countries, such as noncom-
municable diseases, including cancer, car-
diovascular disease and stroke, diabetes,
and obesity [45–50] The challenge of
building effective new R&D&D arrange-
ments in the twenty-first century for all
health needs of all people should be
informed by past developments in malaria.
The most relevant developments to draw
upon are the challenges of filling the
institutional gaps within the global health
system to link R&D with delivery; of
effectively connecting local and interna-
tional researchers; and finally of ensuring
support for the generation of global public
goods for global health. A step in that
direction has recently been taken by the
leading national research agencies of a
number of developed and developing
nations. These have come together to form
the Global Alliance for Chronic Diseases
[50], with a pledge to invest in research in a
coordinated manner, and to scale up
promising interventions to achieve targeted
goals of disease reduction.
Conclusions
In this paper, we have reviewed the
century-long effort to research malaria, to
develop tools for control, and to imple-
ment them. It is clear from our review that
support for and inclusion of local research
institutions in global health research is
essential to develop well-adapted health
tools and to strengthen collaborations
between global and local actors in imple-
mentation. Such support and inclusion is a
necessary precursor to the emergence of
stronger and more integrated global re-
search, development, and delivery, which
we have termed the R&D&D system. The
role of WHO in this global system must
evolve as a partnership with other actors.
Buildinganeffective globalhealth system
takes times. It required decades to build up
research capacity in malaria-endemic
countries to the present level, when local
researchers can play an integral role in
malaria R&D&D. Investments in capacity
building in other relatively neglected areas,
such as noncommunicable diseases, must
begin today if we expect similar dividends
in the future.
R&D must connect closely to the
challenges of implementation. The histor-
ical divide between academic research,
industry development, and those who
implement in the real world cannot
continue if ‘‘acting in time,’’ translating
knowledge into action, is a critical goal.
Those in the R&D world must understand
what the control community has to deal
with, and the latter need to know what is
in the R&D pipeline in order to identify
the delivery constraints that must be
solved.
Enlightened leadership within organiza-
tions comes with a commitment to scaling
up the level of R&D and capacity-building
investments, harnessing the potential
gained from connecting researchers in
the North and the South, and articulating
the messages to decision makers and the
general public to gain support. The new
Global Alliance for Chronic Disease
appears to have heard the message, as
these issues are highlighted in its mandate.
Finally, the case study of malaria
suggests that a multiplicity of partnership
models is useful, particularly for diseases
that require multiple interventions and
continuing R&D. The global health sys-
tem of the future must identify ways to
include those who suffer from diseases,
those who contribute to R&D, and those
who deliver interventions, sharing the
responsibility to link better knowledge
with action for those in need.
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